Indian Patent Office Disallows Patent for Boehringer Ingelheim’s HIV Drug, Nevirapine - (21 Oct 2015)
Indian Patent Office has disallowed Germany's Boehringer Ingelheim a patent on its HIV drug, Nevirapine, sold as Viramune XR (extended release), yet again thwarting attempts by Big Pharma for "exclusivity" extension on their patented drugs to reportedly block entry of affordable generics.
Tags : BOEHRINGER INGELHEIM PATENT HIV DRUG NEVIRAPINE
Share : 
|